China License Out

Announced Date: 2024-06-05 (June 5, 2024) Asset Name: Two ADC asset （ARR-173, ARR-421） Licensor: Jiangsu Alphamab … [China BD 2024] Alphamab and ArriVent enters a 615.5 million USD License on two preclinical ADC assets, ARR-173 and ARR-421Read more

Announced Date: 2024-05-16 (May 16, 2024) Asset Name: JYP0015  (ERAS-0015) Licensor (Seller): Joyo Pharmatech (China) Licensee … [China BD 2024] Joyo Pharma and Erasca enters a License on Pan-RAS molecular glue JYP0015 (ERAS-0015)Read more

Announced Date: 2024-05-16 (May 16, 2024) Asset Name: ERAS-4001 Licensor (Seller): Medshine Discovery (China) Licensee (Buyer): … [China BD 2024] Medshine and Erasca enters a License on selective KRAS inhibitor ERAS-4001Read more

Announced Date: 2024-01-07 (January 7, 2024) Asset Name: Two RNAi programs  (RNA interference) Licensor: Argo (Shanghai … [China BD 2024] Argo and Novartis enters a 4 billion USD license on two RNAi programsRead more

Announced Date: 2024-01-04 (January  4, 2024) Asset Name: AVZO-021 (ARTS-021) Licensor (Seller): Allorion Therapeutics (China) Licensee … [China BD 2024] Allorion and Avenzo enters a 1 billion USD License on CDK2 Inhibitor AVZO-021 (ARTS-021)Read more

Announced Date: 2024-01-04 (January 4, 2024) Asset Name: ISM5043 (MEN2312)  Licensor: InSilico Medicine (China) Licensee (Buyer): … [China BD 2024] Insilico Medicine and Menarini (Stemline) enters a 512 million USD license on a  preclinical KAT6 inhibitor ISM5043 (MEN2312) Read more

Announced Date: 2024-01-02 (January 2, 2024) Asset Name: YL211 (RG6648) Licensor: MediLink (MediLink Therapeutics, China) Licensee … [China BD 2024] MediLink and Roche enters a 1 billion USD license on c-Met ADC YL211 (RG6648)Read more

Announced Date: 2024-01-02 (January 2, 2024) Asset Name: Undisclosed Licensor (Seller): Allorion Therapeutics (China) Licensee (Buyer): AstraZeneca … [China BD 2024] Allorion and AstraZeneca enters an Option and Global License on EGFR L858R Allosteric Inhibitor AssetRead more